Mark Durkan – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Mark Durkan on 2016-02-19.

To ask the Secretary of State for Health, what discussions his Department has had with (a) NICE and (b) NHS England on the availability of Erbitux for metastatic colorectal cancer patients.

George Freeman

The Department has regular discussions with both NHS England and the National Institute for Health and Care Excellence (NICE) on a wide range of issues including the availability of cancer drugs.

NICE is currently updating its technology appraisal guidance on the use of Erbitux (cetuximab) for colorectal cancer along with guidance on another drug Vectibix (panitumumab) (TA240) for previously untreated metastatic colorectal cancer. The anticipated publication date for NICE’s final updated guidance is April 2016.

NHS England is responsible for the operational management of the Cancer Drugs Fund. Erbitux is available in England through the Fund for the first line treatment of metastatic colorectal cancer subject to certain criteria including those indications not approved under TA176.